Imagine you’re out on a weekend bike ride, enjoying the fresh air and the rhythm of the pedals. Suddenly, you feel a strange ache in your leg, but you keep going, thinking it’s nothing serious.

By the end of the week, that ache escalates to flu-like symptoms and a fever. Your blood pressure plummets, and you’re rushed to the ER. Within hours, you undergo the first of eight surgeries. 

Your doctors debate whether to amputate your leg. 

You spend 4 days in the ICU, followed by a month in the hospital.

Your life is changed forever.

This is the brutal reality of sepsis—a condition that can turn a minor infection into a life-threatening emergency in hours.

At Eliaz Therapeutics, we’re fighting to change this reality.

Our solution: XGal-3®, an FDA-designated Breakthrough Device designed to stop sepsis in its tracks. Unlike conventional treatments that only manage symptoms, XGal-3® removes Galectin-3, the protein driving the deadly inflammatory cascade. 

By targeting the root cause, XGal-3® has the potential to save millions of lives and transform the standard of care in sepsis.

Don’t miss this opportunity to join us in this mission, while securing maximum ownership potential.

With gratitude,

The Eliaz Therapeutics Team